European Commission approves Tecvayli monotherapy from first relapse in multiple myeloma

The European Commission has approved Johnson & Johnson's Tecvayli monotherapy from first relapse in multiple myeloma, moving the bispecific antibody into an earlier treatment setting.
Tecvayli (teclistamab) is now authorised in the European Union as monotherapy for adults with relapsed or refractory multiple myeloma after at least one prior therapy, expanding its use beyond later-line treatment.
In the Phase III MajesTEC-9 study, teclistamab reduced the risk of disease progression or death by 71% and the risk of death by 40% compared with standard-of-care regimens, supporting its use from the second-line setting.
Field | Content |
Article Type | Approvals |
Regulatory Authority | European Commission |
Regulatory Decision | Marketing authorisation indication extension |
Announcement Date | 23 October 2026 |
Company | Johnson & Johnson |
Drug Name | Tecvayli |
Generic Name | Teclistamab |
Therapeutic Modality | Bispecific antibody |
Therapeutic Area | Haematology; oncology |
Approved Indication | Monotherapy for adults with relapsed or refractory multiple myeloma after at least one prior therapy |
Patient Population | Adults with relapsed or refractory multiple myeloma |
Minimum Prior Treatment | At least one prior therapy |
Treatment Setting | From first relapse; second-line and later |
Treatment Regimen | Tecvayli monotherapy |
Supporting Clinical Study | Phase III MajesTEC-9 |
Comparator | Standard-of-care regimens |
Progression or Death Risk Reduction | 71% relative risk reduction |
Death Risk Reduction | 40% relative risk reduction |
Geography | European Union |
Previous Regulatory Context | Tecvayli was previously authorised in later-line multiple myeloma settings; this monotherapy extension is distinct from the Tecvayli plus daratumumab approval |
What Happened | The European Commission expanded Tecvayli's monotherapy indication to adults with relapsed or refractory multiple myeloma after at least one prior treatment. |
Why It Matters | The decision makes a bispecific antibody treatment option available earlier in the European multiple myeloma care pathway. |
Clinical Evidence | MajesTEC-9 reported a 71% reduction in progression or death risk and a 40% reduction in death risk versus standard-of-care regimens. |
Key Takeaway | Tecvayli monotherapy can now be used from first relapse in eligible EU patients, supported by Phase III evidence. |
What to Watch | European reimbursement decisions, treatment sequencing, specialist centre adoption, safety management and long-term outcomes. |
Primary Source | Johnson & Johnson Innovative Medicine |
Primary Source URL | https://www.jnj.com/innovativemedicine/emea/media-center/press-releases/european-commission-approves-johnson-johnsons-tecvayli-teclistamab-monotherapy-for-relapsed-refractory-multiple-myeloma-expanding-treatment-options-from-first-relapse |
Relevant Date | 23 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comentarios